TY - JOUR
T1 - The role of multimodal treatment in Crohn′s disease patients with perianal fistula
T2 - a multicentre retrospective cohort study
AU - Sebastian, Shaji
AU - Black, Christopher
AU - Pugliese, Daniela
AU - Armuzzi, Alessandro
AU - Sahnan, Kapil
AU - Elkady, Soad M.
AU - Katsanos, Kostas H.
AU - Christodoulou, Demitrios K.
AU - Selinger, Christian
AU - Maconi, Giovanni
AU - Fearnhead, Nicola S.
AU - Kopylov, Uri
AU - Davidov, Yana
AU - Bosca-Watts, Marta M.
AU - Ellul, Pierre
AU - Muscat, Martina
AU - Karmiris, Konstantinos
AU - Hart, Ailsa L.
AU - Danese, Silvio
AU - Ben-Horin, Shomron
AU - Fiorino, Gionata
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Background: Treatment paradigms for Crohn′s disease with perianal fistulae (CD-pAF) are evolving. Aims: To study the impact of multimodality treatment in CD-pAF on recurrence rates and the need for re-interventions and to identify predictive factors for these outcomes. Methods: This was a multinational multicentre retrospective cohort study. Multimodality approach was defined as using a combination of medical treatments (anti-TNFs ± immunomodulators ± antibiotics) along with surgical approach (examination under anaesthesia (EUA) ± seton drainage) at diagnosis of CD-pAF. Univariable and multivariable analyses were performed for variables indicative of the need for reintervention. Results: A total of 253 patients were included. 65% of patients received multimodality approach. Multimodality treatment resulted in complete fistula healing in 52% of patients. Re-intervention was needed in 27% of patients with simple and in 40.3% of those with complex fistula. On multivariable analysis multimodality treatment (OR: 0.35, 95% CI: 0.17-0.57, P = 0.001), seton removal (OR: 0.090, 95% CI: 0.027-0.30, P = 0.0001, therapy with infliximab (OR: 0.19, 95% CI: 0.06-0.64, P = 0.007), and therapy with adalimumab (OR: 0.12, "95% CI: 0.026-0.56, P = 0.007) were predictive of avoiding repeat surgery. Proctitis (OR: 3.76, 95% CI: 1.09-12.96, P = 0.03) was predictive of the need for radical surgery (proctectomy, diverting stoma) while multimodality treatment reduced the need for radical surgery (OR: 0.21, 95% CI: 0.05-0.81, P = 0.02). Conclusions: Multimodality treatment, anti-TNFs use, and removal of setons after multimodality treatment can result in improved outcomes in CD patients with perianal fistulae and reduce the need for repeat surgery and radical surgery.
AB - Background: Treatment paradigms for Crohn′s disease with perianal fistulae (CD-pAF) are evolving. Aims: To study the impact of multimodality treatment in CD-pAF on recurrence rates and the need for re-interventions and to identify predictive factors for these outcomes. Methods: This was a multinational multicentre retrospective cohort study. Multimodality approach was defined as using a combination of medical treatments (anti-TNFs ± immunomodulators ± antibiotics) along with surgical approach (examination under anaesthesia (EUA) ± seton drainage) at diagnosis of CD-pAF. Univariable and multivariable analyses were performed for variables indicative of the need for reintervention. Results: A total of 253 patients were included. 65% of patients received multimodality approach. Multimodality treatment resulted in complete fistula healing in 52% of patients. Re-intervention was needed in 27% of patients with simple and in 40.3% of those with complex fistula. On multivariable analysis multimodality treatment (OR: 0.35, 95% CI: 0.17-0.57, P = 0.001), seton removal (OR: 0.090, 95% CI: 0.027-0.30, P = 0.0001, therapy with infliximab (OR: 0.19, 95% CI: 0.06-0.64, P = 0.007), and therapy with adalimumab (OR: 0.12, "95% CI: 0.026-0.56, P = 0.007) were predictive of avoiding repeat surgery. Proctitis (OR: 3.76, 95% CI: 1.09-12.96, P = 0.03) was predictive of the need for radical surgery (proctectomy, diverting stoma) while multimodality treatment reduced the need for radical surgery (OR: 0.21, 95% CI: 0.05-0.81, P = 0.02). Conclusions: Multimodality treatment, anti-TNFs use, and removal of setons after multimodality treatment can result in improved outcomes in CD patients with perianal fistulae and reduce the need for repeat surgery and radical surgery.
UR - http://www.scopus.com/inward/record.url?scp=85053510706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053510706&partnerID=8YFLogxK
U2 - 10.1111/apt.14969
DO - 10.1111/apt.14969
M3 - Article
C2 - 30226271
AN - SCOPUS:85053510706
SN - 0269-2813
VL - 48
SP - 941
EP - 950
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 9
ER -